Unbiased Science Podcast - The ABCs of The FDA: America’s Public Health Regulatory Agency скачать в хорошем качестве

Unbiased Science Podcast - The ABCs of The FDA: America’s Public Health Regulatory Agency

(Airdate 11/13/2024) In this episode, Dr. Jessica Steier and Dr. Sarah Scheinman welcome Dr. Namandjé Bumpus, Principal Deputy Commissioner of the FDA, who shares insights into the agency's operations and her path from academia to FDA leadership. The scientists explore the complexities of drug approval processes, the FDA's organizational structure, and its commitment to safety and transparency. Dr. Bumpus discusses the agency's efforts to advance health equity and adapt to emerging technologies, while addressing the critical challenge of maintaining public trust. This conversation offers listeners a unique glimpse into the inner workings of the FDA and its role in protecting public health. All sources and show notes can be found at https://www.unbiasedscipod.com/episodes/ Join this channel to get access to perks:    / @unbiasedscipod   Find us on all social media platforms! Substack: https://theunbiasedscipod.substack.com/ Facebook:   / unbiasedscipod   Twitter:   / unbiasedscipod   LinkedIn:   / posts   Instagram:   / unbiasedscipod   TikTok:   / unbiasedscipod   Spotify: https://open.spotify.com/show/7JMSODg... Link to our shop for Unbiased Science merch and our personally recommended items for you: https://unbiasedscipod.carrd.co/ (00:00) Introduction (03:31) Dr. Bumpus' Academic and Professional Journey (06:19) Transition from Academia to FDA Leadership (09:10) The Role of Pharmacology in Public Health (12:26) Overview of FDA Offices and Centers (15:10) Understanding the Drug Approval Process (18:12) Post-Market Surveillance and Drug Safety (21:20) Building Trust in Government Agencies (24:27) Examples of FDA's Impact on Public Health (27:16) Ensuring Transparency in FDA Processes (30:27) The Human Foods Program and Its Importance (33:08) Adapting to Rapidly Evolving Technologies (36:16) Challenges Facing the FDA and Public Health (38:42) Final Thoughts